Condition
Acute Lymphoblastic Leukemia Not Having Achieved Remission
Total Trials
3
Recruiting
2
Active
2
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 100/100
Termination Rate
33.3%
1 terminated out of 3 trials
Success Rate
0.0%
-86.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
0
Data Visualizations
Phase Distribution
2Total
Not Applicable (1)
P 1 (1)
Trial Status
Recruiting2
Terminated1
Clinical Trials (3)
Showing 3 of 3 trials
NCT07371403Not ApplicableRecruiting
MB-CART19.1 in Relapsed/Refractory Acute Lymphoblastic Leukemia
NCT04049383Phase 1Terminated
CAR-20/19-T Cells in Patients With Relapsed/Refractory B Cell ALL
NCT05809284Recruiting
Determining the Mechanisms of Loss of CAR T Cell Persistence
Showing all 3 trials